Barclays lowered the firm’s price target on Clarivate (CLVT) to $2.40 from $4 and keeps an Underweight rating on the shares. The company’s planned sale of its Life Sciences and Healthcare unit brings deal risk in this market, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLVT: